2 weeks Ago By ABMN Staff
Russell Investments Group Ltd. lifted its stake in Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX – Free Report ) by 60.
1% in the 4th quarter, Holdings Channel reports. The firm owned 265,927 shares of the company’s stock after purchasing an additional 99,807 shares during the quarter. Russell Investments Group Ltd.
’s holdings in Amneal Pharmaceuticals were worth $2,100,000 at the end of the most recent reporting period. A number of other institutional investors have also recently added to or reduced their stakes in AMRX. JPMorgan Chase & Co.
lifted its position in shares of Amneal Pharmaceuticals by 149.7% during the 3rd quarter. JPMorgan Chase & Co.
now owns 1,297,094 shares of the company’s stock valued at $10,792,000 after acquiring an additional 777,568 shares during the period. Barclays PLC increased its stake in Amneal Pharmaceuticals by 134.1% in the 3rd quarter.
Barclays PLC now owns 296,384 shares of the company’s stock valued at $2,466,000 after purchasing an additional 169,756 shares in the last quarter. State Street Corp raised its holdings in Amneal Pharmaceuticals by 3.8% during the third quarter.
State Street Corp now owns 3,514,721 shares of the company’s stock worth $29,242,000 after purchasing an additional 127,753 shares during the last quarter. China Universal Asset Management Co. Ltd.
purchased a new stake in Amneal Pharmaceuticals during the fourth quarter worth $520,000. Finally, Geode Capital Management LLC grew its holdings in Amneal Pharmaceuticals by 11.1% in the third quarter.
Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock valued at $31,511,000 after purchasing an additional 378,136 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.
Amneal Pharmaceuticals Stock Up 2.5 % Shares of NASDAQ:AMRX opened at $7.36 on Friday.
The company has a market capitalization of $2.28 billion, a P/E ratio of -10.82 and a beta of 1.
06. The stock’s fifty day simple moving average is $8.10 and its 200-day simple moving average is $8.
24. Amneal Pharmaceuticals, Inc. has a 52-week low of $5.
18 and a 52-week high of $9.48. Wall Street Analysts Forecast Growth AMRX has been the subject of several research reports.
Barclays lifted their price target on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, March 3rd.
JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $9.00 to $12.
00 in a research report on Monday, February 24th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Amneal Pharmaceuticals presently has an average rating of “Buy” and an average target price of $10.
80. Read Our Latest Report on AMRX Insiders Place Their Bets In related news, Director Gautam Patel sold 80,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $8.
14, for a total transaction of $651,200.00. Following the completion of the transaction, the director now owns 1,888,886 shares of the company’s stock, valued at approximately $15,375,532.
04. This represents a 4.06 % decrease in their ownership of the stock.
The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink . Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $8.
35, for a total transaction of $41,750,000.00. Following the transaction, the insider now directly owns 48,578,209 shares in the company, valued at approximately $405,628,045.
15. This represents a 9.33 % decrease in their position.
The disclosure for this sale can be found here . In the last three months, insiders sold 5,160,000 shares of company stock valued at $43,113,200. Company insiders own 26.
56% of the company’s stock. About Amneal Pharmaceuticals ( Free Report ) Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE.
The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. Featured Articles Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc.
( NASDAQ:AMRX – Free Report ). Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
